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Abstract  
 
KDM6B/JMJD3 is a histone H3 lysine demethylase with an important gene regulatory 
role in development and physiology. Here we show that human JMJD3 expression is 
induced by the active vitamin D metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) 
and that JMJD3 modulates the gene regulatory action of this hormone. 1,25(OH)2D3 
activates the JMJD3 gene promoter and increases the level of JMJD3 RNA in human 
cancer cells. JMJD3 upregulation was strictly dependent on vitamin D receptor (VDR) 
expression and was abolished by cycloheximide. In SW480-ADH colon cancer cells, 
JMJD3 knockdown or expression of an inactive mutant JMJD3 fragment decreased the 
induction by 1,25(OH)2D3 of several target genes and of an epithelial adhesive phenotype. 
Moreover, JMJD3 knockdown upregulated the epithelial-to-mesenchymal transition 
inducers SNAIL1 and ZEB1 and the mesenchymal markers Fibronectin and LEF1, while 
it downregulated the epithelial proteins E-cadherin, Claudin-1 and Claudin-7. 
Additionally, JMJD3 knockdown abolished the nuclear export of -catenin and the 
inhibition of -catenin transcriptional activity caused by 1,25(OH)2D3. Importantly, the 
expression of JMJD3 correlated directly with that of VDR and inversely with that of 
SNAI1 in a series of 96 human colon tumours. Our results indicate for the first time that 
an epigenetic gene coding for a histone demethylase such as JMJD3 is a VDR co-target 
that partially mediates the effects of 1,25(OH)2D3 on human colon. 
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INTRODUCTION 
 
Histone methylation on specific lysine residues is a crucial point for gene expression in 
eukaryotic cells that is controlled by the opposite action of histone methyltransferases (KMTs), 
such as Polycomb group proteins, and demethylases (KDMs), such as LSD1 and the family of 
Jumonji (Jmj) C domain-containing enzymes (1). Several KDMs have been implicated in 
development, differentiation or stem cell renewal, and their mutation or deregulation have been 
linked to cancer and other diseases (2-7). 
 JMJD3 (KDM6B) and UTX (KDM6A) specifically demethylates di- and tri-methyl-
lysine 27 on histone H3 (H3K27me2/3) (8-10). The presence of H3K27me3 at transcriptional 
sites usually correlates with gene repression (7,11,12), and Polycomb-mediated H3K27 
methylation pre-marks genes for DNA methylation and silencing in cancer (13). Thus, JMJD3 
is expected to enable the activation of genes, which indeed occurs for those involved in animal 
body patterning and the inflammatory response (8,10,14,15). Moreover, JMJD3 is induced 
upon activation of the RAS-RAF signalling pathway and contributes to the transcriptional 
activation of the p16
INK4A
 tumour suppressor in diploid fibroblasts (16,17), and it is aberrantly 
overexpressed and seems to be involved in Epstein-Barr virus-associated Hodgkin’s lymphoma 
(18). In addition, JMJD3 appears to have transcriptional effects unrelated to the level of histone 
methylation at least in lipopolysaccharide-stimulated mouse macrophages, and the possibility 
of non-histone substrates and/or other activities of KDMs is emerging (19,20). 
 Many epidemiological and preclinical studies suggest a protective effect of vitamin D 
against several neoplasias, particularly colon cancer, whose confirmation is pending of 
adequate clinical trials (21-23). The active vitamin D metabolite 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) is a hormone with wide gene regulatory effects in higher organisms (24,25), 
which is in line with the expression of the vitamin D receptor (VDR) in over 30 different cell 
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types (26). VDR is a member of the nuclear hormone receptor superfamily of transcription 
factors modulated by ligand, phosphorylation, and perhaps other modifications (27,28). 
Although part of VDR is extranuclear and upon ligand binding can activate signalling 
pathways, these are thought to converge with the regulation of gene transcription as the major 
effect of DNA-bound VDR/1,25(OH)2D3 complexes (29,30). 
 1,25(OH)2D3 is believed to regulate the expression of hundreds of genes but only a 
subset of them seem to contain VDR binding sites (VDRE, vitamin D regulatory elements). In 
addition, very few genes respond to 1,25(OH)2D3 with drastic changes in their transcription 
rate; rather the hormone has a weak, moderate effect that is compatible with a permissive 
action. We hypothesized that this could be related to epigenetic changes: hormone-induced 
alterations at the chromatin level that could facilitate gene transcription regulation by other 
agents. Supporting this, transcriptomic studies by us and others have revealed JARID2/JMJ, 
JARID1A/KDM5A and JMJD2B/KDM4B as candidate 1,25(OH)2D3 targets in human SW480-
ADH colon or SCC25 squamous cell carcinoma cells (31 and our own unpublished results). All 
this led us to investigate the possibility that 1,25(OH)2D3 affects the expression of genes 
controlling epigenetic processes such as those regulating histone modifications. As the 
majority of 1,25(OH)2D3 target genes are induced while only around one-third are repressed, 
we chose histone H3 lysine demethylases to study. 
 Our results show that 1,25(OH)2D3 induces the expression of JMJD3 in several types of 
human cancer cells. The regulation is transcriptional and probably mediated by one or more 
short-lived proteins. Importantly, a knockdown approach has shown that JMJD3 mediates in 
part the induction by 1,25(OH)2D3 of several target genes such as CDH1/E-cadherin and 
CST5/cystatin D and modulates the expression of the epithelial-to-mesenchymal transition 
(EMT) inducers SNAIL1 and ZEB1. Probably as a consequence of these actions, JMJD3 
controls the phenotype of human colon cancer cells. Importantly, the level of expression of 
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VDR and JMJD3 directly correlate in human colon tumours, suggesting that the regulation of 
JMJD3 by 1,25(OH)2D3 may take place in vivo during colon cancer progression and mediates 
at least in part the protective action of 1,25(OH)2D3 against this neoplasia. 
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RESULTS 
 
JMJD3 gene is induced by 1,25(OH)2D3 
To study whether 1,25(OH)2D3 could affect the expression of histone H3 lysine demethylases, 
we analyzed the RNA level of ten JmjC-domain proteins by qRT-PCR in SW480-ADH colon 
cancer cells treated for 4 or 48 h with the hormone. As control, we studied CYP24A1 and 
CDH1/E-cadherin, known to be induced, and CYP27B1, which is repressed by 1,25(OH)2D3. 
We found the strongest change (2 to 3-fold increase at 48 h treatment) for JMJD3, while 
JMJD4 showed only a 25% decrease and the remaining genes were unaffected (Supplementary 
Material, Fig. S1). To investigate in depth the observed effect we first performed time-course 
and dose-curve experiments. A progressive increase in JMJD3 RNA level was detected 
following hormone treatment (10
-7
 M) (Fig. 1A) that was dose-dependent at 48 h (Fig. 1B). 
The general validity and specificity of this finding was examined using a panel of human 
cancer cell lines, investigating the requirement of VDR, and analysing the putative effect of 
other nuclear receptors ligands. A common upregulation (2 to 3-fold) by 1,25(OH)2D3 was 
found in several human colon (SW1417, SW48, KM12C), breast (MCF7, MDA-MB-453, 
MDA-MB-231) and skin (UACC-257) cancer cell lines (Supplementary Material, Fig. S2A). 
No effect of 1,25(OH)2D3 was detected in other cancer cell lines such as HT29 or Caco-2 
(colon), SK-MEL-28 (skin) or AGS (gastric) (not shown). Importantly, no regulation was 
detected in SW620 and SW480-R cells that do not express VDR (32) (Supplementary Material, 
Fig. S2A). Consistently, VDR knockdown by shRNA in SW480-ADH cells abolished the 
increase in JMJD3 RNA expression caused by 1,25(OH)2D3 (Fig. 1C). Finally, neither 
estradiol, progesterone, dexamethasone, triiodothyronine, all-trans- or cis-retinoic acid, or 
docosahexaenoic acid (ligands for estrogen, progesterone, glucocorticoid, thyroid, retinoic or 
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rexinoid receptors, respectively) changed basal JMJD3 RNA expression nor affected the 
induction by 1,25(OH)2D3 (Supplementary Material, Fig. S2B). 
 Next we studied the mechanism of JMJD3 upregulation. To investigate whether the 
effect on JMJD3 RNA level was due to the activation of the gene promoter we studied the 
effect of 1,25(OH)2D3 in SW480-ADH cells that were transfected with a series of plasmids 
containing distinct sequences of the promoter upstream of the luciferase reporter gene (17). 
Promoter constructs P1-P5 containing -3,422, -2,439, -2,314, -2,224, and -2,173 bp 
immediately upstream of the JMJD3 transcription start site active in macrophages (MF-TSS) 
were activated by the hormone (Fig. 1D). On the other hand, the activity of P6 and P7 
constructs spanning -2,102 and -1,428 bp upstream of this site, or P8 containing -2,928 bp 
upstream the JMJD3 start site active in embryonic stem cells (ESC-TSS), were not affected by 
1,25(OH)2D3 (Fig. 1D). This suggests that 1,25(OH)2D3 induces JMJD3 transcription via 
sequences located from -2,173 to -2,102 bp upstream the MF-TSS. This region of the promoter 
contains sites for RAP1, Sp1, Krox-20, ETF, C/EBP, and AP-1 transcription factors and is 
crucial for the induction of JMJD3 promoter by BRAF (17). However, the involvement of 
other sequences not contained in the constructs studied cannot be ruled out. The protein 
synthesis inhibitor cycloheximide (CHX) blocked the increase in JMJD3 RNA by 
1,25(OH)2D3 (Fig. 1E). The long treatment with CHX that is needed because of the slow 
kinetics of JMJD3 induction makes the requirement of intermediary short-lived protein(s) 
suggestive, but not definitive. In addition, no statistically significant VDR binding to three 
putative VDREs revealed by in silico analysis of the JMJD3 gene (-28697-
AGGCCATTTAGTTCA; -1073-TGACCTCTACCACCT; +9183-TGACCCAGCCGACCC 
respect to the ESC-TSS) was found by means of chromatin immunoprecipitation assays 
(Supplementary Material, Fig. S3A and B). This negative result further supports an indirect 
mechanism of regulation. 
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JMJD3 modulates the gene regulatory effects of 1,25(OH)2D3 
To study the importance of JMJD3 in 1,25(OH)2D3 action we generated SW480-ADH cells 
stably expressing JMJD3 shRNA (shJMJD3) or a non-targeting shRNA (shControl). First, we 
confirmed a stable downregulation of JMJD3 expression, which did not affect VDR RNA 
expression (Fig. 2A). 
 As a major effect of 1,25(OH)2D3 in human colon and breast carcinoma cells is the 
induction of E-cadherin protein, which causes a morphological change to an adhesive epithelial 
phenotype (32-34) we analyzed these biological parameters in shJMJD3 cells. The increase in 
both intercellular adhesion and E-cadherin protein expression by 1,25(OH)2D3 was partially 
inhibited in shJMJD3 cells (Fig. 2B), and was co-incident with changes in the tubulin 
cytoskeleton and cell morphology (Fig. 2B). In line with this, the induction of CDH1/E-
cadherin RNA and also that of CYP24A1 and CST5/cystatin D, two other 1,25(OH)2D3 targets 
(35,36), was inhibited in shJMJD3 cells (Fig. 2C). JMJD3 knockdown decreased also the basal 
expression of CDH1/E-cadherin and CST5/cystatin D (Fig. 2C). These effects were reproduced 
at the promoter and protein levels: the activity of the CDH1/E-cadherin gene promoter was 
lower in shJMJD3 than in shControl cells (Fig. 2D); likewise, the basal and induced expression 
of E-cadherin and cystatin D proteins was lower in shJMJD3 cells (Fig. 2E). In contrast, 
however, JMJD3 knockdown did not affect the expression of VDR protein (Fig. 2E), 
indicating that JMJD3 is not equally required for the activation of all genes and that the 
inhibition of the gene regulatory action of 1,25(OH)2D3 in shJMJD3 cells is not a consequence 
of diminished VDR expression. 
 To exclude off-target effects of the knockdown approach and confirm the role of 
JMJD3 mediating 1,25(OH)2D3 action, we generated cells expressing ectopically a HA-tagged 
inactive JMJD3 C-terminal region harbouring a His to Ala1388 mutation in the iron-binding 
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center (MUT 1141-1641) (10). As control, we generated also cells expressing the same wild-
type JMJD3 polypeptide (WT 1141-1614) or and empty vector (Mock). Expression of the 
corresponding exogenous polypeptides was confirmed by qRT-PCR and Western blot 
(Supplementary Material, Fig. S4A and B). As happened for JMJD3 knockdown, neither MUT 
1141-1614 nor WT 1141-1641 JMJD3 polypeptides altered the expression of VDR RNA or 
protein (Supplementary Material, Fig. S4A and B). Importantly, MUT 1141-1641 cells 
behaved as shJMJD3 cells in terms of 1,25(OH)2D3-induced phenotype change, basal and 
1,25(OH)2D3-induced CDH1/E-cadherin, CST5/cystatin D and CYP24A1 RNA and protein 
expression, and CDH1/E-cadherin promoter activity (Supplementary Material, Fig. S4C-F). 
These effects were specific, as they did not take place in cells expressing the WT 1141-1641 
JMJD3 polypeptide (Supplementary Material, Fig. S4C-F). 
 
JMJD3 knockdown enhances the expression of epithelial-to-mesenchymal transition 
inducers 
The finding that JMJD3 knockdown affected CDH1/E-cadherin expression and cell phenotype 
led us to investigate the possibility that these effects could be due to the regulation of genes 
such as SNAI1, SNAI2, ZEB1 or ZEB2 encoding transcriptional repressors (SNAIL1, SNAIL2, 
ZEB1, ZEB2) of CDH1/E-cadherin that are EMT inducers (37). Interestingly, JMJD3 
knockdown increased the expression of SNAI1, ZEB1 and ZEB2 RNA without affecting that of 
SNAI2 RNA (Fig. 3A), and increased also SNAIL1 and ZEB1 protein levels (Fig. 3B). 
Consistent also with a role of JMJD3 preventing EMT, shJMJD3 cells had higher RNA levels 
of the mesenchymal genes Lymphoid Enhancer-binding Factor 1 (LEF1) and Fibronectin 
(FN1), and lower RNA and protein levels of the epithelial genes CLDN1/Claudin-1, 
CLDN7/Claudin-7 and CDH1/E-cadherin (Fig. 3C and D). 
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JMJD3 knockdown inhibits the antagonism of the Wnt/-catenin pathway by 
1,25(OH)2D3 
We and others have reported that 1,25(OH)2D3 antagonizes the Wnt/-catenin signalling 
pathway by promoting a direct VDR--catenin interaction and nuclear export of -catenin, 
which together lead to inhibition of the transcriptional activity of -catenin/T-cell factor (TCF) 
complexes (32,33,38-40). Further emphasizing the requirement for JMJD3 in 1,25(OH)2D3 
action, both -catenin nuclear export and inhibition of its transcriptional activity by 
1,25(OH)2D3 were blocked in shJMJD3 cells (Fig. 4A and B). Expectedly from the effect of 
Wnt/-catenin pathway promoting cell proliferation, 1,25(OH)2D3 caused a stronger inhibition 
of the proliferation of shControl cells than of shJMJD3 cells (45% and 29% respectively; P < 
0.001) (Fig. 4C). In line with the reduced proliferation of cells that express SNAIL1 and 
undergo EMT (41,42), shJMJD3 cells grew less than shControl cells (19%; P < 0.001) (Fig. 
4C). 
  
Analysis of the expression of JMJD3, VDR and SNAI1 in human colon tumours 
To translate the findings in cultured cells to the in vivo setting, we studied the expression of 
JMJD3, VDR and SNAI1 genes in matched normal and tumour tissue samples of a series of 96 
colon cancer patients. 
 Lower JMJD3 RNA expression in tumour versus normal tissue was found in 54/96 
(56.3%) patients. No significant correlation was detected between the level of JMJD3 
expression and any clinical parameter, but a tendency existed between low JMJD3 expression 
and poor tumour differentiation (ANOVA test, P = 0.082). In line with previous studies (43-
45), VDR expression was downregulated in tumour versus normal tissue in two-thirds (64/96, 
66.7%) of patients while, in contrast, SNAI1 was upregulated in a similar percentage of cases 
(62.2%).  
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 Interestingly, a significant direct correlation was found between the RNA levels of 
JMJD3 and VDR (Pearson correlation coefficient r = 0.245, P = 0.016) (Fig. 5A). In contrast, 
the expression of JMJD3 and SNAI1 RNA showed a strong inverse trend with borderline 
significance (ANOVA test, P = 0.057) in 82 informative cases (Fig. 5B). 
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DISCUSSION 
 
In this study we demonstrate that the human histone H3 lysine demethylase JMJD3 gene is 
induced by 1,25(OH)2D3 in a panel of cancer cell lines. Data obtained using a series of JMJD3 
promoter constructs suggest that 1,25(OH)2D3 induces JMJD3 transcription via sequences 
located from -2,173 to -2,102 bp upstream the MF-TSS. The blockade of JMJD3 induction 
using CHX and the absence of VDR binding to three putative VDREs present in the JMJD3 
gene suggest an indirect mechanism of regulation. However, the long CHX treatments needed 
due to the slow kinetics of JMJD3 regulation, could affect VDR expression and therefore the 
possibility of a direct regulation of JMJD3 by 1,25(OH)2D3 can not be excluded. Also, other 
putative VDREs may exist. We show that JMJD3 is implicated in the regulation of several 
1,25(OH)2D3 target genes such as CDH1/E-cadherin and CST5/cystatin D. Moreover, 
knockdown experiments indicate that JMJD3 contributes to maintain the adhesive epithelial 
cell phenotype, as its downregulation augments the expression of SNAIL1 and ZEB1 
transcription factors. The study of JMJD3 expression in normal and tumour tissue of colon 
cancer patients strongly supports its role during the progression of this neoplasia. Furthermore, 
the direct correlation between the expression levels of JMJD3 and VDR suggests that 
1,25(OH)2D3 regulates JMJD3 in the human colon. 
 Recent studies have shown the importance of histone methyltransferases and 
demethylases in the gene regulatory effects of several nuclear receptors (28). Transcriptional 
activation of nuclear receptor target genes requires changes in the local chromatin environment 
that are at least partially consequence of the direct or indirect recruitment by the receptors of 
histone methylases and demethylases. In addition, several histone-modifying enzymes target 
estrogen and retinoic acid nuclear receptors and/or their coactivators and corepressors (SRC3, 
CBP/p300...) (28). Altogether, these findings suggest strongly that histone methyltransferases 
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and demethylases mediate the ligand-dependent regulation of gene expression by some nuclear 
receptors (46). For VDR, dynamic modification of H3K27me3 has recently been reported in 
the regulation of CDKN1A by 1,25(OH)2D3 in normal prostate cells (47). In line with this and 
in a cancer context, our results demonstrate for the first time that a KDM modulates ligand-
activated VDR effects on gene transcription. From the screening of a large number of JmjC-
containing proteins (Supplementary Material, Fig. S1), it is conceivable that KDMs others than 
JMJD3 can be also involved and thus, that the gene regulatory activity of VDR/1,25(OH)2D3 
can be fine tuned by the combinatorial action of several histone modifying enzymes, probably 
in a cell-type dependent manner. 
 Mechanistically, the induction of JMJD3 may have several different effects on 
1,25(OH)2D3 action that are not mutually exclusive. First, to contribute to a local chromatin 
environment that facilitates the expression of target genes via H3K27me2/3 demethylation. 
CDH1/E-cadherin and CST5/cystatin D may be examples. Second, to demethylate VDR and/or 
any of its coregulators, although no data supporting this exist. Third, to alter chromatin of 
genes other than those transcriptionally-regulated by 1,25(OH)2D3 that may, however, act 
additively or synergistically with this hormone. Finally, the proposed existence of JMJD3 
effects unrelated to histone demethylation (20) opens the possibility to distinct, unknown 
mechanism(s) of modulation of 1,25(OH)2D3  action. 
 Interestingly, the first genome-wide studies performed to identify VDR binding sites by 
ChIP-Seq have revealed a huge number of them in the human and mouse genomes (48,49). As 
it happens with other transcription factors, only a subset of VDR binding sites are expected to 
be functional, and this is thought to depend on the epigenetic status of the cell (50). 
Conceivably, JMJD3 may contribute to generate a chromatin structure favourable to gene 
activation by 1,25(OH)2D3 and so, its induction by 1,25(OH)2D3 would be a pre-requisite to 
ensure an optimal gene regulatory action of the hormone. 
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 Studies by Kato’s group have proposed DNA methylation as part of the mechanism of 
gene repression by 1,25(OH)2D3 (51), while Gadd45a, a well-known  1,25(OH)2D3 target gene, 
promotes epigenetic gene activation by repair-mediated DNA demethylation in Xenopus laevis 
(52). Our work, however, links a histone demethylase to gene activation by this hormone. 
 Moreover, the analysis of global transcriptomic studies available in the Oncomine 
database (http://www.oncomine.org) has previously evidenced reduced JMJD3 expression in 
several human cancers relative to normal tissues including several hematopoietic malignancies 
and lung and liver carcinomas (16,17). Our study, however, is the first one to measure JMJD3 
expression individually in a series of human cancer patients under well-controlled conditions, 
and together with the results generated in cultured colon cancer cells, it strengthens the 
previously suggested nature of JMJD3 as a tumour suppressor (16,17). 
 In conclusion, our study uncovers the epigenetic regulator JMJD3 as a new 
1,25(OH)2D3 target gene that in turn integrates with the gene regulatory actions of this 
hormone. Disruption of this link in human cancer cells may play a role during colon 
tumourigenesis and potentially offer new therapeutic targets to delay tumour progression. 
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MATERIALS AND METHODS 
 
Cells and cell culture 
Human cancer cell lines SW480-ADH and SW480-R (32), SW620, SW1417, HCT116, HT29, 
KM12C, Caco-2, MCF7, MDA-MB-231, MDA-MB-453, UACC-257, SK-MEL-28 and AGS 
were cultured in DMEM plus 10% foetal bovine serum (Invitrogen, Paisley, UK), except 
MDA-MB-453 that was cultured in DMEM:F12 (Invitrogen). SW480-ADH shVDR and 
shControl cells were described previously (29). All experiments using 1,25(OH)2D3 were 
performed in medium supplemented with charcoal-treated serum. Phase-contrast images of 
cultured cells were captured with a Leica DC300 digital camera mounted on an inverted Leitz 
Labovert FS Microscope. All images were processed using Adobe Photoshop CS5 software 
(Adobe Systems, San José, CA). 
 
Antibodies and reagents 
We used primary mouse monoclonal antibodies against E-cadherin, -catenin (BD 
Biosciences, San Jose, CA), -tubulin (Sigma-Aldrich, St. Louis, MO) and HA (Covance, 
Princeton, NJ); rat monoclonal antibodies against VDR (Millipore, Billerica, MA); rabbit 
polyclonal antibodies against Claudin-1 and Claudin-7 (Zymed-Invitrogen) and goat polyclonal 
antibodies against ZEB1, -actin and Lamin B (Santa Cruz Biotechnology, Santa Cruz, CA). 
Secondary antibodies used: Alexa 488-conjugated goat anti-mouse (Molecular Probes-
Invitrogen); HRP-conjugated anti-rabbit (MP Biomedicals, Solon, OH), anti- mouse (Promega, 
Madison, WI), anti-goat and anti-rat (Santa Cruz Biotechnology). F-actin was stained with 
Phalloidin-TRITC and nuclei using DAPI (Molecular Probes-Invitrogen). Cycloheximide, 
estradiol, dexamethasone, progesterone, triiodothyronine, all-trans-retinoic acid, cis-retinoic 
acid and docosahexaenoic acid were from Sigma-Aldrich. 
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Patients and tumour samples 
Normal and tumour tissue samples from 96 colon cancer patients were obtained immediately 
after surgery, immersed in RNA later (Applied Biosystems, Carlsbad, CA), snap-frozen in 
liquid nitrogen and stored at -80ºC until processing. Tumours were considered sporadic cases 
because no clinical antecedents of Familial Adenomatous Polyposis (FAP) were reported and 
those with clinical criteria of hereditary non-polyposis colorectal cancer (HNPCC) 
(Amsterdam criteria) were excluded. Tumours were examined by two different pathologists to: 
(a) confirm adenocarcinoma diagnostic and presence of at least 75% of tumour tissue in the 
sample, (b) establish the histological level of the tumour, and (c) verify the absence of tumour 
cells in normal tissue. All patients gave written informed consent. The protocol was approved 
by the Research Ethics Board of the Hospital Universitario Puerta de Hierro, Majadahonda, 
Madrid, Spain. 
 
Transfection 
Cells were transfected using the jetPEI reagent (PolyPlus Transfection, Illkirch, France). 
Firefly (Luc) and Renilla reniformis luciferase (Rluc) activities were measured separately using 
the Dual Luciferase kit (Promega). Luc activity was normalized to the Rluc activity. All 
experiments were performed at least in triplicate. The -987/+92 promoter construct for 
CDH1/E-cadherin was previously reported (32). The 4X-VDRE-DR3-tk-Luc construct was 
provided by Dr. C. Carlberg (Kuopio, Finland). To study -catenin/TCF transcriptional activity 
we used the TOP-Flash and FOP-Flash plasmids provided by Dr. H. Clevers, (Utrecht, The 
Netherlands). JMJD3 gene promoter constructs were provided by Dr. K. Helin (Copenhagen, 
Denmark). 
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 SW480-ADH cells stably expressing JMJD3 were generated by transfection with pRC-
JMJD3-1141-1641-WT-HA, pRC-JMJD3-1141-1641-MUT-HA or the empty vector (kindly 
provided by Dr. G. Natoli, Milan, Italy) followed by selection with 0.5 mg/ml of G418 (Sigma-
Aldrich) for two weeks. HA expression was confirmed by Western blot and that of JMJD3 
RNA by qRT-PCR using primers for a common sequence to JMJD3 1141-1641 WT and MUT 
(Forward: GGAGACCTTTATCGCCTCTG; Reverse: TCCCTTTCACCTTGGCATT). 
 
Gene silencing 
To knockdown JMJD3 expression, SW480-ADH cells were seeded in 150 mm dishes and 
infected with lentiviral particles containing a U6 promoter driving an short hairpin (shRNA) 
targeting JMJD3 RNA. Control cells were infected with lentivirus bearing a non-targeting 
shRNA that activates the RISC complex and the RNA interference pathway but that contains at 
least five mismatched nucleotides compared with any human gene. Mission shRNA lentiviral 
particles against human JMJD3 and scramble negative control (Sigma-Aldrich) were used. 
After infection cells were selected with 1 g/l puromycin (Sigma-Aldrich) for one week. 
 
Quantitative RT-PCR 
RNA was extracted from ~30 mg of tumour or normal tissue and from cultured cells using 
RNeasy mini kit (Qiagen, Hilden, Germany). RNA was retrotranscribed using the High 
Capacity cDNA Archive Kit (Applied Biosystems).  Primers used for qRT-PCR are listed in 
Supplementary Material, Table S1. We also used the following TaqMan probes: JMJD3 
(Hs00389749_m1), CYP24A1 (Hs00167999_m1), VDR (Hs01045840_m1), SNAI1 
(Hs00195591_m1), CST5 (Hs00983867_m1), UTX (Hs00958902_m1), 18S (4310893E) 
(Applied Biosystems). RNA expression values were normalized versus the housekeeping gene 
succinate dehydrogenase complex subunit A (SDHA) or with the 18S ribosomal RNA (18S). In 
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experiments with cell lines we used the 7500 StepOne Plus Real-Time PCR System using the 
TaqMan or SYBR Gene Expression Master Mix (Applied Biosystems). Thermal cycling was 
initiated with a denaturation step of 95ºC for 10 min and consisted of 40 cycles (denaturation at 
95ºC 10 s, annealing and elongation at 60ºC for 60 s). RNA expression analysis for human 
colon samples was performed in a LightCycler apparatus using the LightCycler-FastStart DNA 
MasterPLUS SYBR Green I Kit (Roche Diagnostics, Basel, Switzerland). Thermal cycling was 
initiated with a denaturation step of 95ºC for 10 min and consisted of 40 cycles of denaturing at 
94ºC 0 s; annealing at 59ºC (JMJD3) 60ºC (VDR) 68ºC (SNAI1) or 59ºC (SDHA) for 5 s and 
elongation at 72ºC for 5 s. All experiments were performed in triplicate. 
 
Western blot 
Proteins were separated by SDS-PAGE. After blotting onto a PVDF membrane, proteins were 
revealed following the ECL technique (GE Healthcare, Chalfont St. Gills, UK). Different 
exposure times of the films were used to ensure that bands were not saturated. Quantification 
of the films was done by densitometry using ImageJ software. 
 
Immunofluorescence and confocal microscopy 
Cells were fixed in methanol at -20ºC for 1 min (E-cadherin, -Tubulin and -Catenin 
staining) or in p-formaldehyde (F-Actin staining) for 15 min and permeabilized in 0.2% Triton 
X-100, and then washed four times in PBS. Cells were incubated with the primary antibodies 
diluted in PBS for 1 h at 37ºC. After four washes in PBS, cells were incubated with secondary 
antibodies for 45 min at room temperature and washed three times in PBS. For F-Actin 
staining cells were incubated with Phalloidin-TRITC for 15 min at 37ºC and washed in PBS. 
Finally, coverslips containing the cells were mounted using Prolong Gold antifade reagent 
(Molecular Probes-Invitrogen).  Cell imaging was performed on a Leica TCS SP5 DMI6000 
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microscope using argon ion (488 nm), HeNe (543 nm) and violet diode (405 nm) lasers. 
Images were acquired sequentially by direct register using Leica Confocal Software (LAS AF). 
 
Cell proliferation assay (MTT) 
This assay is based on the cleavage of the yellow [3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl] 
tetrazolium bromide salt (MTT) to purple formazan crystals by metabolic active cells. Ten 
thousand cells were seeded in 24-well plates and treated with 1,25(OH)2D3 or vehicle. At 
indicated times cells were incubated with the MTT solution (final concentration of 0.5 mg/ml, 
Roche Diagnostics) for 4 h at 37ºC. After this incubation period, a water-insoluble formazan 
dye is formed. After solubilization with 500 l of 0.04 M HCl isopropanol during 30 min at 
R/T, the formazan dye was quantified using a scanning microplate spectrophotometer 
(VersaMax, Molecular Devices. Sunnyvale, CA). The absorbance was measured as 570-630 
nm. All experiments were performed using triplicates. 
 
In silico screening of VDREs and chromatin immunoprecipitation assays 
The sequence surrounding the transcription start site (TSS) of the human JMJD3 gene was 
obtained from the ENSEMBL database. This TSS was coincident with the ESC-TSS described 
by Agger et al. (17). A region spanning 50 kb upstream and 50 kb downstream of the TSS was 
analyzed for putative VDREs as previously described (53,54). The effect of single nucleotide 
variations on the classical VDRE sequence (AGTTCAnnnAGTTCA) suggested RGKTCA 
(R=A/G and K=G/T) as the consensus hexameric core sequence for VDREs. We screened for 
hexamers pairs in DR3, DR4 and ER6 to ER9 orientation fitting the RGKTCA consensus 
sequence or having at most two deviations from it. We selected the three theoretically best 
VDREs (-28697, -1073 and +9183) based on their predicted binding strength, location relative 
to the TSS and conservation across multiple species. 
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 X-ChIP was used to measure the association of VDR and RNA polymerase II to the 
three VDREs and the TSS of the JMJD3 gene as previously described (55). Rabbit polyclonal 
anti-VDR and anti-RNA polymerase II antibodies (both from Abcam, Cambridge, UK) were 
used for immunoprecipitation. q-PCR was performed in the 7900 HT Sequence Detection 
System (Applied Biosystems) using SensiMix (dT) Kit and SYBR Green (both from Quantace, 
London, UK). Primers used were as follows: -28697 (Forward:  
AGGGCAACTATATCCCTAAGGT; Reverse: TGGAGCGTTTTAATGCTGTC), -1073 
(Forward: CTAGCCTGAAGCTCCCTTCC; Reverse: ACCAAGGCCTCCTTCCTAAG), 
+9183 (Forward: CTTGCGAGACCCTTGTGG; Reverse: AGTCGCTCAGTCCCACTGTC) 
and TSS (Forward: CCCCACCTCTAACTGACTTTTT; Reverse: 
TGGGGTACAACAGACCACAG). Thermal cycling was initiated with a denaturation step at 
95ºC for 10 min and consisted of 40 cycles of denaturing at 95ºC 15 s; annealing at 58ºC (-
28697, TSS) or 62ºC (-1073, +9183) for 30 s and elongation at 72ºC for 30 s. All experiments 
were performed in triplicate. 
 
Statistical analysis 
Results are expressed as mean ± SEM unless otherwise specified. Statistical significance was 
assessed by two-tailed unpaired Student’s t test using the GraphPad Instat3 program. 
Differences were considered significant when P < 0.05. The single asterisk indicates P < 0.05, 
the double asterisk P < 0.01, and the triple asterisk P < 0.001. 
 The correlation between the tumour versus normal ratio (T/N) of JMJD3 RNA 
expression and that of VDR in samples from colon cancer patients was studied using the 
Pearson correlation coefficient. Since SNAI1 RNA was not detected in any normal tissue, the 
T/N cannot be calculated and its expression was evaluated as presence or absence in tumour 
tissue. Therefore, correlation between SNAI1 tumour expression and T/N of JMJD3 expression 
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was studied using ANOVA test. Associations between clinicopathological parameters and 
JMJD3 gene expression were studied using ANOVA test. Statistical analysis of gene 
expression data from colon cancer patients was performed using SPSS software (SPSS, 
Chicago, IL). Differences were considered statistically significant when P < 0.05. 
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SUPPLEMENTARY MATERIAL 
Supplementary Material is available at HMG online. 
 
ACKNOWLEDGEMENTS 
We thank Drs. H. Clevers, C. Carlberg, G. Natoli and K. Helin for kindly providing us 
reagents, and T. Martínez for technical assistance. We also thank Drs. J.L. Thorne, L.P. 
O’Neill and B.M. Turner for their help with X-ChIP experiments, and Dr. M. Heinäniemi for 
VDRE in silico analysis. This work was supported by grants of the Ministerio de Ciencia e 
Innovación of Spain [SAF2010-18302 to A.M., SAF2010-20750 to F.B.]; and the Fondo 
Europeo de Desarrollo Regional-Instituto de Salud Carlos III [RD06/0020/0009 to A.M., 
RD06/0020/0020 to F.B.]. 
 
Conflict of Interest statement. None declared. 
 
 
 23 
REFERENCES 
 
1. Nottke, A., Colaiacovo, M.P. and Shi, Y. (2009) Developmental roles of the histone lysine 
demethylases. Development, 136, 879-889. 
2. Yamane, K., Tateishi, K., Klose, R.J., Fang, J., Fabrizio, L.A., Erdjument-Bromage, H., 
Taylor-Papadimitriou, J., Tempst, P. and Zhang, Y. (2007) PLU-1 is an H3K4 demethylase 
involved in transcriptional repression and breast cancer cell proliferation. Mol. Cell, 25, 
801-812. 
3. Peng, J.C. and Karpen, G.H. (2009) Heterochromatic genome stability requires regulators 
of histone H3 K9 methylation. PLoS Genet., 5, e1000435. 
4. van Haaften, G., Dalgliesh, G.L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, 
S., Hardy, C., O'Meara, S., Teague, J. et al. (2009) Somatic mutations of the histone 
H3K27 demethylase gene UTX in human cancer. Nat. Genet., 41, 521-523. 
5. Dalgliesh, G.L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., 
Edkins, S., Hardy, C., Latimer, C. et al. (2010) Systematic sequencing of renal carcinoma 
reveals inactivation of histone modifying genes. Nature, 463, 360-363. 
6. Qi, H.H., Sarkissian, M., Hu, G.Q., Wang, Z., Bhattacharjee, A., Gordon, D.B., Gonzales, 
M., Lan, F., Ongusaha, P.P., Huarte, M. et al. (2010) Histone H4K20/H3K9 demethylase 
PHF8 regulates zebrafish brain and craniofacial development. Nature, 466, 503-507. 
7. Chi, P., Allis, C.D. and Wang, G.G. (2010) Covalent histone modifications--miswritten, 
misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer, 10, 457-469. 
8. Agger, K., Cloos, P.A., Christensen, J., Pasini, D., Rose, S., Rappsilber, J., Issaeva, I., 
Canaani, E., Salcini, A.E. and Helin, K. (2007) UTX and JMJD3 are histone H3K27 
demethylases involved in HOX gene regulation and development. Nature, 449, 731-734. 
 24 
9. Hong, S., Cho, Y.W., Yu, L.R., Yu, H., Veenstra, T.D. and Ge, K. (2007) Identification of 
JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc. 
Natl. Acad. Sci. USA, 104, 18439-18444. 
10. De Santa, F., Totaro, M.G., Prosperini, E., Notarbartolo, S., Testa, G. and Natoli, G. (2007) 
The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-
mediated gene silencing. Cell, 130, 1083-1094. 
11. Swigut, T. and Wysocka, J. (2007) H3K27 demethylases, at long last. Cell, 131, 29-32. 
12. Li, B., Carey, M. and Workman, J.L. (2007) The role of chromatin during transcription. 
Cell, 128, 707-719. 
13. Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, 
E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B.E. et al. (2007) Polycomb-mediated 
methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. 
Nat. Genet., 39, 232-236. 
14. Lan, F., Bayliss, P.E., Rinn, J.L., Whetstine, J.R., Wang, J.K., Chen, S., Iwase, S., Alpatov, 
R., Issaeva, I., Canaani, E. et al. (2007) A histone H3 lysine 27 demethylase regulates 
animal posterior development. Nature, 449, 689-694. 
15. Lee, M.G., Villa, R., Trojer, P., Norman, J., Yan, K.P., Reinberg, D., Di Croce, L. and 
Shiekhattar, R. (2007) Demethylation of H3K27 regulates polycomb recruitment and H2A 
ubiquitination. Science, 318, 447-450. 
16. Barradas, M., Anderton, E., Acosta, J.C., Li, S., Banito, A., Rodriguez-Niedenfuhr, M., 
Maertens, G., Banck, M., Zhou, M.M., Walsh, M.J. et al. (2009) Histone demethylase 
JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev., 
23, 1177-1182. 
17. Agger, K., Cloos, P.A., Rudkjaer, L., Williams, K., Andersen, G., Christensen, J. and 
Helin, K. (2009) The H3K27me3 demethylase JMJD3 contributes to the activation of the 
 25 
INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev., 
23, 1171-1176. 
18. Anderton, J.A., Bose, S., Vockerodt, M., Vrzalikova, K., Wei, W., Kuo, M., Helin, K., 
Christensen, J., Rowe, M., Murray, P.G. et al. (2011) The H3K27me3 demethylase, 
KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma. 
Oncogene, 30, 2037-2043. 
19. Huang, J. and Berger, S.L. (2008) The emerging field of dynamic lysine methylation of 
non-histone proteins. Curr. Opin. Genet. Dev., 18, 152-158. 
20. De Santa, F., Narang, V., Yap, Z.H., Tusi, B.K., Burgold, T., Austenaa, L., Bucci, G., 
Caganova, M., Notarbartolo, S., Casola, S. et al. (2009) Jmjd3 contributes to the control of 
gene expression in LPS-activated macrophages. Embo J., 28, 3341-3352. 
21. Deeb, K.K., Trump, D.L. and Johnson, C.S. (2007) Vitamin D signalling pathways in 
cancer: potential for anticancer therapeutics. Nat. Rev. Cancer, 7, 684-700. 
22. Giovannucci, E. (2011) The epidemiology of vitamin D and cancer risk. In Feldman, D., 
Pike, J.W. and Adams, J.S. (eds.), Vitamin D, 3
rd
 edition. Elsevier - Academic Press, San 
Diego, CA, USA, Vol. 2, pp. 1569-1590. 
23. IARC Working Group Reports (2008) Vitamin D and cancer. WHO Press, Lyon, France, 
Vol. 5. 
24. Carlberg, C. and Seuter, S. (2009) A genomic perspective on vitamin D signaling. 
Anticancer Res., 29, 3485-3493. 
25. Krishnan, A.V., Trump, D.L., Johnson, C.S. and Feldman, D. (2010) The role of vitamin D 
in cancer prevention and treatment. Endocrinol. Metab. Clin. North. Am., 39, 401-418, 
table of contents. 
26. Norman, A.W. (2008) From vitamin D to hormone D: fundamentals of the vitamin D 
endocrine system essential for good health. Am. J. Clin. Nutr., 88, 491S-499S. 
 26 
27. Thorne, J. and Campbell, M.J. (2008) The vitamin D receptor in cancer. Proc. Nutr. Soc., 
67, 115-127. 
28. Wu, S.C. and Zhang, Y. (2009) Minireview: role of protein methylation and demethylation 
in nuclear hormone signaling. Mol. Endocrinol., 23, 1323-1334. 
29. Ordóñez-Morán, P., Larriba, M.J., Pálmer, H.G., Valero, R.A., Barbáchano, A., Duñach, 
M., García de Herreros, A., Villalobos, C., Berciano, M.T., Lafarga, M. et al. (2008) 
RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, 
phenotype, and Wnt pathway in colon cancer cells. J. Cell Biol., 183, 697-710. 
30. Ordóñez-Morán, P. and Muñoz, A. (2009) Nuclear receptors: genomic and non-genomic 
effects converge. Cell Cycle, 8, 1675-1680. 
31. Wang, T.T., Tavera-Mendoza, L.E., Laperriere, D., Libby, E., MacLeod, N.B., Nagai, Y., 
Bourdeau, V., Konstorum, A., Lallemant, B., Zhang, R. et al. (2005) Large-scale in silico 
and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol. 
Endocrinol., 19, 2685-2695. 
32. Pálmer, H.G., González-Sancho, J.M., Espada, J., Berciano, M.T., Puig, I., Baulida, J., 
Quintanilla, M., Cano, A., García de Herreros, A., Lafarga, M. et al. (2001) Vitamin D3 
promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and 
the inhibition of beta-catenin signaling. J. Cell Biol., 154, 369-387. 
33. Xu, H., McCann, M., Zhang, Z., Posner, G.H., Bingham, V., El-Tanani, M. and Campbell, 
F.C. (2009) Vitamin D receptor modulates the neoplastic phenotype through antagonistic 
growth regulatory signals. Mol. Carcinog., 48, 758-772. 
34. Pendás-Franco, N., González-Sancho, J.M., Suárez, Y., Aguilera, O., Steinmeyer, A., 
Gamallo, C., Berciano, M.T., Lafarga, M. and Muñoz, A. (2007) Vitamin D regulates the 
phenotype of human breast cancer cells. Differentiation, 75, 193-207. 
 27 
35. Vaisanen, S., Dunlop, T.W., Sinkkonen, L., Frank, C. and Carlberg, C. (2005) Spatio-
temporal activation of chromatin on the human CYP24 gene promoter in the presence of 
1alpha,25-Dihydroxyvitamin D3. J. Mol. Biol., 350, 65-77. 
36. Álvarez-Díaz, S., Valle, N., García, J.M., Peña, C., Freije, J.M., Quesada, V., Astudillo, A., 
Bonilla, F., López-Otín, C. and Muñoz, A. (2009) Cystatin D is a candidate tumor 
suppressor gene induced by vitamin D in human colon cancer cells. J. Clin. Invest., 119, 
2343-2358. 
37. Peinado, H., Olmeda, D. and Cano, A. (2007) Snail, Zeb and bHLH factors in tumour 
progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer, 7, 415-428. 
38. Shah, S., Islam, M.N., Dakshanamurthy, S., Rizvi, I., Rao, M., Herrell, R., Zinser, G., 
Valrance, M., Aranda, A., Moras, D. et al. (2006) The molecular basis of vitamin D 
receptor and beta-catenin crossregulation. Mol. Cell, 21, 799-809. 
39. Egan, J.B., Thompson, P.A., Vitanov, M.V., Bartik, L., Jacobs, E.T., Haussler, M.R., 
Gerner, E.W. and Jurutka, P.W. (2010) Vitamin D receptor ligands, adenomatous polyposis 
coli, and the vitamin D receptor FokI polymorphism collectively modulate beta-catenin 
activity in colon cancer cells. Mol. Carcinog., 49, 337-352. 
40. He, W., Kang, Y.S., Dai, C. and Liu, Y. (2011) Blockade of Wnt/beta-catenin signaling by 
paricalcitol ameliorates proteinuria and kidney injury. J. Am. Soc. Nephrol., 22, 90-103. 
41. Vega, S., Morales, A.V., Ocaña, O.H., Valdés, F., Fabregat, I. and Nieto, M.A. (2004) 
Snail blocks the cell cycle and confers resistance to cell death. Genes Dev., 18, 1131-1143. 
42. Larriba, M.J., Valle, N., Pálmer, H.G., Ordóñez-Morán, P., Álvarez-Díaz, S., Becker, K.F., 
Gamallo, C., García de Herreros, A., González-Sancho, J.M. and Muñoz, A. (2007) The 
inhibition of Wnt/-catenin signalling by 1,25-dihydroxyvitamin D3 is abrogated by 
Snail1 in human colon cancer cells. Endocr. Relat. Cancer, 14, 141-151. 
 28 
43. Peña, C., García, J.M., Silva, J., García, V., Rodríguez, R., Alonso, I., Millán, I., Salas, C., 
García de Herreros, A., Muñoz, A. et al. (2005) E-cadherin and vitamin D receptor 
regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations. Hum. 
Mol. Genet., 14, 3361-3370. 
44. Larriba, M.J., Martín-Villar, E., García, J.M., Pereira, F., Peña, C., García de Herreros, A., 
Bonilla, F. and Muñoz, A. (2009) Snail2 cooperates with Snail1 in the repression of 
vitamin D receptor in colon cancer. Carcinogenesis, 30, 1459-1468. 
45. Pálmer, H.G., Larriba, M.J., García, J.M., Ordóñez-Morán, P., Peña, C., Peiró, S., Puig, I., 
Rodríguez, R., de la Fuente, R., Bernad, A. et al. (2004) The transcription factor SNAIL 
represses vitamin D receptor expression and responsiveness in human colon cancer. Nat. 
Med., 10, 917-919. 
46. Garcia-Bassets, I., Kwon, Y.S., Telese, F., Prefontaine, G.G., Hutt, K.R., Cheng, C.S., Ju, 
B.G., Ohgi, K.A., Wang, J., Escoubet-Lozach, L. et al. (2007) Histone methylation-
dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. 
Cell, 128, 505-518. 
47. Thorne, J.L., Maguire, O., Doig, C.L., Battaglia, S., Fehr, L., Sucheston, L.E., Heinaniemi, 
M., O'Neill, L.P., McCabe, C.J., Turner, B.M. et al. (2011) Epigenetic control of a VDR-
governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-
malignant prostate cells. Nucleic Acids Res., 39, 2045-2056. 
48. Ramagopalan, S.V., Heger, A., Berlanga, A.J., Maugeri, N.J., Lincoln, M.R., Burrell, A., 
Handunnetthi, L., Handel, A.E., Disanto, G., Orton, S.M. et al. (2010) A ChIP-seq defined 
genome-wide map of vitamin D receptor binding: associations with disease and evolution. 
Genome Res., 20, 1352-1360. 
49. Pike, J.W. (2011) Genome-wide principles of gene regulation by the vitamin D receptor 
and its activating ligand. Mol. Cell Endocrinol., in press, doi:10.1016/j.mce.2011.05.012.  
 29 
50. Farnham, P.J. (2009) Insights from genomic profiling of transcription factors. Nat. Rev. 
Genet., 10, 605-616. 
51. Kim, M.S., Kondo, T., Takada, I., Youn, M.Y., Yamamoto, Y., Takahashi, S., Matsumoto, 
T., Fujiyama, S., Shirode, Y., Yamaoka, I. et al. (2009) DNA demethylation in hormone-
induced transcriptional derepression. Nature, 461, 1007-1012. 
52. Barreto, G., Schafer, A., Marhold, J., Stach, D., Swaminathan, S.K., Handa, V., Doderlein, 
G., Maltry, N., Wu, W., Lyko, F. et al. (2007) Gadd45a promotes epigenetic gene 
activation by repair-mediated DNA demethylation. Nature, 445, 671-675. 
53. Matilainen, M., Malinen, M., Saavalainen, K. and Carlberg C. (2005) Regulation of 
multiple insulin-like growth factor binding protein genes by 1alpha,25-dihydroxyvitamin 
D3. Nucleic Acids Res., 33, 5521-5532. 
54. Heinäniemi, M., Uski, J.O., Degenhardt, T. and Carlberg C. (2007) Meta-analysis of 
primary target genes of peroxisome proliferator-activated receptors. Genome Biol., 8, 
R147. 
55. Saramäki, A., Banwell, C.M., Campbell, M.J. and Carlberg C. (2006) Regulation of the 
human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 
receptor. Nucleic Acids Res., 34, 543-554. 
 
 30 
LEGENDS TO FIGURES 
 
Figure 1. 1,25(OH)2D3 induces JMJD3 expression in colon cancer cells. (A) qRT-PCR 
analysis of JMJD3 RNA levels in SW480-ADH cells treated with 10
-7
 M 1,25(OH)2D3 for the 
indicated times. (B) JMJD3 RNA expression in SW480-ADH cells treated with the indicated 
doses of 1,25(OH)2D3 for 48 h. (C) JMJD3 RNA levels in SW480-ADH cells expressing 
shVDR or shControl that were treated with 10
-7
 M 1,25(OH)2D3 or vehicle for 48 h. (D) 
Activity of a series of JMJD3 promoter constructs (P1-P8) (17) in SW480-ADH cells. Cells 
transfected with the indicated construct were incubated with 10
-7
 M 1,25(OH)2D3 or vehicle for 
48 h and the expression of luciferase in cell extracts was estimated. Inset: Scheme of the 
JMJD3 promoter constructs used. Constructs are represented as gray boxes and arrows indicate 
the position of the transcription start site active in embryonic stem cells (ESC-TSS) and in 
macrophages (MF-TSS). (E) JMJD3 RNA levels in SW480-ADH cells pretreated 30 min with 
8 µg/ml cycloheximide (CHX) as indicated and then with 10
-7
 M 1,25(OH)2D3 or vehicle for 
24 or 36 h. In (A-C and E) 18S rRNA expression was used for normalization. Data are 
expressed as the mean  SEM of three independent experiments (A-D) or as mean  SD of a 
representative experiment performed in triplicate (E). 
 
Figure 2. JMJD3 knockdown inhibits the induction of an adhesive epithelial phenotype and 
target genes by 1,25(OH)2D3 without affecting VDR expression. (A) qRT-PCR analysis of the 
RNA levels of JMJD3 and VDR in SW480-ADH shControl and shJMJD3 cells. SDHA was 
used for normalization. Mean  SEM (n = 3). (B) Upper panels, representative phase-contrast 
images of SW480-ADH shControl and shJMJD3 cells treated with 10
-7
 M 1,25(OH)2D3 or 
vehicle for 48 h. Bar: 10 m. Lower panels, representative immunofluorescence and confocal 
microscopy images of E-cadherin and -Tubulin expression in SW480-ADH shControl and 
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shJMJD3 cells treated with 10
-7
 M 1,25(OH)2D3 or vehicle for 48 h. Bar: 10 m. (C) qRT-PCR 
analysis of the RNA levels of CDH1/E-cadherin, CYP24A1 and CST5/cystatin D in SW480-
ADH shControl and shJMJD3 cells treated with 10
-7
 M 1,25(OH)2D3 or vehicle for 8 h. 18S 
was used for normalization. Mean  SEM (n = 3). (D) Activity of the CDH1/E-cadherin 
promoter (-987 to +92 bp) in SW480-ADH shControl and shJMJD3 cells. The cells were 
transfected with the CDH1/E-cadherin promoter construct and the expression of luciferase in 
cell extracts was estimated 48 h later. Mean  SEM (n = 4). (E) Western blot analysis of E-
cadherin, Cystatin D and VDR protein expression in SW480-ADH shControl and shJMJD3 
cells treated with 10
-7
 M 1,25(OH)2D3 or vehicle for 8 or 48 h. -Actin was used as control. 
Numbers refer to the fold-change with respect to untreated shControl cells. The Western blot 
shown correspond to a representative experiment of the three performed. 
 
Figure 3. JMJD3 knockdown increases the expression EMT inducers and mesenchymal 
markers and represses epithelial markers. (A) qRT-PCR analysis of SNAI1, SNAI2, ZEB1 and 
ZEB2 RNA expression in SW480-ADH shControl and shJMJD3 cells. SDHA was used for 
normalization. Mean  SEM (n = 3). (B) Western blot analysis of SNAIL1 and ZEB1 protein 
expression in SW480-ADH shControl and shJMJD3 cells. -Actin and Lamin B were used as 
controls. Numbers show the quantification of two experiments. (C) qRT-PCR analysis of 
LEF1, FN1, CLDN-1/Claudin-1 and CLDN-7/Claudin-7 RNA expression in SW480-ADH 
shControl and shJMJD3 cells. SDHA was used for normalization. Mean  SEM (n = 3). (D) 
Western blot analysis of Claudin-1, Claudin-7 and E-cadherin protein expression in SW480-
ADH shControl and shJMJD3 cells. -Actin and Lamin B were used as controls. Numbers 
show the quantification of two experiments. 
 
 32 
Figure 4. JMJD3 knockdown abrogates the inhibition of Wnt/-catenin signalling and cell 
proliferation by 1,25(OH)2D3. (A) Representative immunofluorescence and confocal 
microscopy images of -catenin and F-actin expression in SW480-ADH shControl and 
shJMJD3 cells treated with 10
-7
 M 1,25(OH)2D3 or vehicle for 48 h. Bar: 10 m. (B) 
Transcriptional activity of -catenin/TCF complexes in SW480-ADH shControl and shJMJD3 
cells treated with 10
-7
 M 1,25(OH)2D3 or vehicle for 72 h. The cells were transfected with the 
TOP-Flash and FOP-Flash reporter plasmids and the ratio of luciferase expression (TOP-
Flash/FOP-Flash) in cell extracts was calculated. Mean  SEM (n = 4). (C) Proliferation of 
SW480-ADH shControl and shJMJD3 cells treated with 10
-7
 M 1,25(OH)2D3 or vehicle for the 
indicated times was estimated by MTT assays. Mean  SEM (n = 4). 
 
Figure 5. Expression levels of JMJD3, VDR and SNAI1 genes in human colon cancer patients. 
RNA levels of JMJD3, VDR and SNAI1 were analyzed by qRT-PCR in normal and tumour 
tissue samples of 96 colon carcinoma patients. Quantification was performed as described in 
Material and Methods. (A) Scattergram showing the relation between JMJD3 and VDR RNA 
levels in each patient. The P value was calculated using the Pearson test. (B) Box-plot of 
JMJD3 expression in tumours expressing or not SNAI1 RNA. Boxes in the plots include values 
in the 25%-75% interval, internal lanes represent the median, and values higher than 1.5 box 
lengths were represented as outliers (o). The P value was calculated using the ANOVA test. 
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LEGENDS TO SUPPLEMENTARY FIGURES  
 
Supplementary Figure 1. Effect of 1,25(OH)2D3 on the expression of ten JmjC-domain 
proteins in colon cancer cells. qRT-PCR analysis of RNA levels in SW480-ADH cells treated 
with 10
-7
 M 1,25(OH)2D3 or vehicle for the indicated times. CYP24A1 and CDH1/E-cadherin 
genes that are induced, and CYP27B1 gene that is repressed by 1,25(OH)2D3 were used as 
controls. SDHA was used for normalization. Mean  SEM (n = 3). 
 
Supplementary Figure 2. 1,25(OH)2D3 induces JMJD3 expression in a panel of human cancer 
cell lines of different origin. (A) qRT-PCR analysis of JMJD3 RNA levels in colon (SW1417, 
SW48, KM12C), breast (MCF7, MDA-MB-453, MDA-MB-231) and skin (UACC-257) cancer 
cells treated with 10
-7
 M 1,25(OH)2D3 or vehicle for 48 h. SW620 and SW480-R cell lines that 
lack VDR expression and do not respond to 1,25(OH)2D3 were used as control. (B) qRT-PCR 
analysis of JMJD3 RNA levels in SW480-ADH cells treated with 10
-7
 M of the indicated 
agents for 48 h. (A and B) 18S rRNA was used for normalization. Data (mean  SD) 
correspond to one representative experiment performed in triplicate. 
 
Supplementary Figure 3. VDR does not bind to three putative VDREs in the human JMJD3 
gene. (A) Genomic location of three putative VDREs (R1, R2 and R3) present in the human 
JMJD3 gene revealed by in silico analysis. VDREs are represented as red boxes and their 
sequence is indicated. Blue boxes correspond to exons (small boxes: noncoding exons; large 
boxes: coding exons). ESC-TSS: transcription start site active in embryonic stem cells; MF-
TSS: transcription start site active in macrophages. (B) X-ChIP analysis of the association of 
VDR (left panels) or RNA polymerase II (right panels) to the three VDREs and the 
transcription start site (TSS) of the human JMJD3 gene in SW480-ADH cells treated with 10
-7
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M 1,25(OH)2D3 or vehicle for the indicated times. Enrichment was measured by q-PCR with 
specific primers to each region and normalized over input. Mean  SEM (n = 3). 
 
Supplementary Figure 4. Ectopic expression of the mutant inactive JMJD3 MUT 1141-1641 
polypeptide inhibits the induction of an adhesive epithelial phenotype and target genes by 
1,25(OH)2D3 without affecting VDR expression. (A) qRT-PCR analysis of the RNA levels of 
JMJD3 and VDR in Mock, WT 1141-1641 and MUT 1141-1641 SW480-ADH cells. SDHA 
and 18S were used for normalization. Data (mean  SD) correspond to one representative 
experiment performed in triplicate. (B) Western blot analysis of the ectopic expression of WT 
1141-1641 and MUT 1141-1641 JMJD3 polypeptides and of VDR in Mock, WT 1141-1641 
and MUT 1141-1641 SW480-ADH cells treated with 10
-7
 M 1,25(OH)2D3 or vehicle for 48 h. 
-Actin and Lamin B were used as controls. (C) Left panels, representative phase-contrast 
images of Mock, WT 1141-1641 and MUT 1141-1641 SW480-ADH cells treated with 10
-7
 M 
1,25(OH)2D3 or vehicle for 48 h. Bar: 15 m. Right panels, representative immunofluorescence 
and confocal microscopy images of E-cadherin protein expression in the same cells. Bar: 10 
m. (D) qRT-PCR analysis of the RNA levels of CDH1/E-cadherin, CYP24A1 and 
CST5/cystatin D in Mock, WT 1141-1641 and MUT 1141-1641 SW480-ADH cells treated 
with 10
-7
 M 1,25(OH)2D3 or vehicle for 8 h. 18S was used for normalization. Mean  SEM (n = 
3). (E) Activity of the CDH1/E-cadherin promoter in SW480-ADH Mock, WT 1141-1641 and 
MUT 1141-1641 cells. The cells were transfected with the CDH1/E-cadherin promoter 
construct (-987 to +92 bp) and the expression of luciferase in cell extracts was estimated 48 h 
later. Mean  SEM (n = 3). (F) Western blot analysis of E-cadherin and Cystatin D protein 
expression in SW480-ADH Mock, WT 1141-1641 and MUT 1141-1641 cells treated with 10
-7
 
M 1,25(OH)2D3 or vehicle for 48 h. -Actin was used as control. Numbers refer to the fold-
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change with respect to untreated Mock cells. The Western blot shown correspond to a 
representative experiment of the three performed. 
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TABLES 
 
Supplementary Table 1. Sequence of primers used for qRT-PCR. 
 
Gene Forward Primer Reverse Primer 
KDM2A GAAGAGGAGGAGGAGGAGGA GCTGAGGTAGCGGAAGACAG 
KDM3A TCAAGAAAACCCAGCAGACC CACCACATCCCCAAGAAACT 
JMJD1C TACATCACGACGCAGGTCTC CTTGGGAGTTCATTGCTGGT 
JMJD3 TGCTCCGTCAACATCAACAT CTTCTGCTCCGTCAACATCA 
JMJD4 GTGGGGAATGGACTCTCGT GACTCTCGGTCAAGGACAGG 
MINA TCAGAAAAGGGCAACGATTC CCAACCAAGGAGCCAAAGTA 
PHF2 GAGGCAAGAAGAAAGGGAAGA GGGCACACTCAGGACACTCT 
UTY CCACCAACTTCACCATACCC GGAGGAAAGAAAGCATCACG 
KDM5C GTGGTGGAGGAAGGTGGTTA AGCGTAGCAAGGAGCCAATA 
CYP27B1 CCTCAGCCACTGTTCTGTCC CCAGCGTATTTTTGGGGATA 
VDR TTGCCATACTGCTGGACGC GGCTCCCTCCACCATCATT 
FN1 GGGAGCCTCGAAGAGCAAG AACCGGGCTTGCTTTGAC 
LEF1 CGAAGAGGAAGGCGATTTAG GTCTTGGCCACCTCGTGTC 
CLDN1 TTGGTCTCTATCTCCTGAATC ATTGTGTGGGAAGGTCAA 
CLDN7 AGCTTGCTCCTGGTATGGC CAATAAAGAGGCAGGGCC 
SDHA TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG 
CDH1 AGAACGCATTGCCACATACACTC CATTCTGATCGGTTACCGTGATC 
SNAI1 CACTATGCCGCGCTCTTTC GGTCGTAGGGCTGCTGGAA 
SNAI2 GGCAAGGCGTTTTCCAGAC GCTCTGTTGCAGTGAGGGC 
ZEB1 GCCAATAAGCAAACGATTCTG TTTGGCTGGATCACTTTCAAG 
ZEB2 TATGGCCTACACCTACCCAAC AGGCCTGACATGTAGTCTTGTG 
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ABBREVIATIONS 
1,25(OH)2D3, 1,25-dihydroxyvitamin D3; JMJD3, jumonji domain containing 3; KDM6B, 
lysine (K)-specific demethylase 6B 
 
